Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
All edits
Edits on 6 Jan, 2024
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+334 characters)
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
Article
Study summary
This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on delivery location. The secondary objective is to evaluate delivery with fasting versus fed status.
Infobox
Is a
NCT Number
Trial Recruitment Size
80
Trial Sponsor
Clinical Trial Start Date
March 31, 2017
0Primary Completion Date
May 5, 2017
0Study Completion Date
April 3, 2018
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Other0
Official Website
Official Name
A Phase 1, Open-Label, Randomized, 2×2 Crossover Study of Pharmacodynamics Comparing the Impact of Tablet Size and Fasting Status With an Oral Human Influenza A/California/04/2009 (H1N1) HA Adenoviral-Vector Based Vaccine and dsRNA Adjuvant0
Last Updated
May 30, 2018
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Find more entities like Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.